Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma

被引:73
|
作者
Hoellein, Alexander [1 ]
Fallahi, Mohammad [2 ]
Schoeffmann, Stephanie [1 ]
Steidle, Sabine [1 ]
Schaub, Franz X. [2 ]
Rudelius, Martina [3 ,4 ]
Laitinen, Iina [5 ]
Nilsson, Lisa [6 ]
Goga, Andrei [7 ]
Peschel, Christian [1 ,8 ,9 ]
Nilsson, Jonas A. [6 ]
Cleveland, John L. [2 ]
Keller, Ulrich [1 ,8 ,9 ]
机构
[1] Tech Univ Munich, Dept Med 3, D-80290 Munich, Germany
[2] Scripps Res Inst, Dept Canc Biol, Jupiter, FL USA
[3] Univ Wurzburg, Inst Pathol, Wurzburg, Germany
[4] Univ Wurzburg, Clin Canc Ctr Mainfranken, D-97070 Wurzburg, Germany
[5] Tech Univ Munich, Dept Nucl Med, D-80290 Munich, Germany
[6] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Canc Ctr, Dept Surg, Gothenburg, Sweden
[7] Univ Calif San Francisco, Dept Cell Tissue Biol, San Francisco, CA 94143 USA
[8] German Canc Consortium DKTK, Heidelberg, Germany
[9] German Canc Res Ctr, Heidelberg, Germany
基金
美国国家卫生研究院; 瑞典研究理事会;
关键词
C-MYC; SYNTHETIC LETHALITY; TUMOR SUPPRESSION; PROTEIN-SYNTHESIS; GENE-EXPRESSION; CANCER; DRIVEN; INHIBITION; PATHWAY; ONCOGENE;
D O I
10.1182/blood-2014-06-584524
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myc oncogenic transcription factors (c-Myc, N-Myc, and L-Myc) coordinate the control of cell growth, division, and metabolism. In cancer, Myc overexpression is often associated with aggressive disease, which is in part due to the destruction of select targets by the ubiquitin-proteasome system (eg, SCFSkp2 -directed destruction of the Cdk inhibitor p27(Kip1)). We reasoned that Myc would also regulate SUMOylation, a related means of posttranslational modification of proteins, and that this circuit would play essential roles in Myc-dependent tumorigenesis. Here, we report marked increases in the expression of genes that encode regulators and components of the SUMOylation machinery in mouse and human Myc-driven lymphomas, resulting in hyper-SUMOylation in these tumors. Further, inhibition of SUMOylation by genetic means disables Myc-induced proliferation, triggering G2/M cell-cycle arrest, polyploidy, and apoptosis. Using genetically defined cell models and conditional expression systems, this response was shown to be Myc specific. Finally, in vivo loss-of-function and pharmacologic studies demonstrated that inhibition of SUMOylation provokes rapid regression of Myc-driven lymphoma. Thus, targeting SUMOylation represents an attractive therapeutic option for lymphomas with MYC involvement.
引用
收藏
页码:2081 / 2090
页数:10
相关论文
共 50 条
  • [41] Myc Commands an Aurora Kinase - Sumoylation Circuit Required for B Cell Lymphoma Growth and Survival
    Hoellein, Alexander
    Schoeffmann, Stephanie
    Mohammad, Fallahi
    Cleveland, John L.
    Gloeckner, Johannes
    Ueffing, Marius
    Rudelius, Martina
    Peschel, Christian
    Keller, Ulrich
    BLOOD, 2014, 124 (21)
  • [42] Blocked B cell differentiation and emigration support the early growth of Myc-induced lymphomas
    Brandvold, KA
    Ewert, DL
    Kent, SC
    Neiman, P
    Ruddell, A
    ONCOGENE, 2001, 20 (25) : 3226 - 3234
  • [43] Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
    Lin, Pei
    Dickason, Timothy J.
    Fayad, Luis E.
    Lennon, Patrick A.
    Hu, Peter
    Garcia, Mar
    Routbort, Mark J.
    Miranda, Roberto
    Wang, Xumei
    Qiao, Wei
    Medeiros, L. Jeffrey
    CANCER, 2012, 118 (06) : 1566 - 1573
  • [44] Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation
    Shi, Jin
    Stover, James S.
    Whitby, Landon R.
    Vogt, Peter K.
    Boger, Dale L.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (21) : 6038 - 6041
  • [45] The diagnostic and prognostic role of MYC translocations in aggressive B-cell lymphoma
    Klapper, W.
    ONKOLOGIE, 2011, 34 : 87 - 88
  • [46] Identification of Pathological Markers of MYC Translocation in Large B-cell Lymphoma
    Kirkwood, K.
    Hart, A.
    Hendry, L.
    Day, F.
    Bauld, R.
    Raffan, M.
    Krajewski, A.
    Goodlad, J.
    JOURNAL OF PATHOLOGY, 2010, 222 : S5 - S5
  • [47] Notch-Regulated Enhancers in B-Cell Lymphoma Activate MYC and Potentiate B-Cell Receptor Signaling
    Ryan, Russell J. H.
    Petrovic, Jelena
    Rausch, Dylan
    Lareau, Caleb
    Lee, Winston
    Donohue, Laura
    Christie, Amanda L.
    Gillespie, Shawn
    Kluk, Michael J.
    Nardi, Valentina
    Faryabi, Robert B.
    Hochberg, Ephraim P.
    Weinstock, David M.
    Bernstein, Bradley E.
    Aster, Jon C.
    Pear, Warren S.
    BLOOD, 2016, 128 (22)
  • [48] Immunohistochemical and Cytogenetic Evaluation of MYC in Diffuse Large B-Cell Lymphoma
    Caponetti, Gabriel
    Perry, Anamarija
    Smith, Lynette
    Bast, Martin
    Dave, Bhavana
    Fu, Kai
    Greiner, Timothy
    Weisenburger, Dennis
    LABORATORY INVESTIGATION, 2015, 95 : 338A - 339A
  • [49] MYC in diffuse large B-cell lymphoma: always the bad guy?
    Kersten, Marie Jose
    Guikema, Jeroen E. J.
    LEUKEMIA & LYMPHOMA, 2015, 56 (11) : 3003 - 3004
  • [50] Immunohistochemical and Cytogenetic Evaluation of MYC in Diffuse Large B-Cell Lymphoma
    Caponetti, Gabriel
    Perry, Anamarija
    Smith, Lynette
    Bast, Martin
    Dave, Bhavana
    Fu, Kai
    Greiner, Timothy
    Weisenburger, Dennis
    MODERN PATHOLOGY, 2015, 28 : 338A - 339A